BioNTech extends COVID-19 vaccine trial in China to end-Oct
BEIJING (Reuters) – Vaccine developer BioNTech has prolonged by six months to October a Part II scientific trial of its COVID-19 vaccine in China, a registry of such trials confirmed.
The vaccine, based mostly on messenger RNA (mRNA) know-how, is without doubt one of the most generally used worldwide towards COVID, however has but to obtain an approval in China, which has relied solely on domestically developed vaccine.
China’s main medical specialists have urged authorities to retain powerful zero-COVID measures in order to purchase time and step up vaccination charges and develop new remedies, within the battle on the nation’ largest outbreak.
The Part II trial on the vaccine’s security and immunogenicity started in late 2020, concentrating on completion by the top of April, however this was prolonged to the top of October, in response to a database managed by an company beneath the U.S. Nationwide Institutes of Well being.
BioNTech and its Chinese language associate, Shanghai Fosun Pharmaceutical Group, weren’t instantly accessible to remark.
(Reporting by Roxanne Liu in Beijing and Patricia Weiss in Frankfurt; Modifying by Clarence Fernandez)
